Betty Pettersen
Alexion Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Nutrition and Health in Aging, Histone Deacetylase Inhibitors Research, GDF15 and Related Biomarkers, Computational Drug Discovery Methods, Receptor Mechanisms and Signaling
Most-Cited Works
- → GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates(2020)170 cited
- → Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)(2011)107 cited
- → Discovery of the Potent and Selective M1 PAM-AgonistN-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects(2016)83 cited
- → Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity(2017)58 cited
- → Identification of Multiple 5-HT4Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease(2012)42 cited
- → Standardized UV–vis spectra as the foundation for a threshold-based, integrated photosafety evaluation(2013)32 cited
- → Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy(2016)17 cited
- → Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment(2025)14 cited
- → GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats(2013)9 cited
- → A cross-industry survey on photosafety evaluation of pharmaceuticals after implementation of ICH S10(2021)7 cited